LTR Pharma has today announced that it has successfully completed a A$25 million placement to sophisticated and institutional investors to accelerate SPONTAN®’s commercialisation. These funds will accelerate the Company’s progress in the U.S.; increase R&D investment for product portfolio expansion and manufacturing scale-up; and assist with launching an innovative telehealth platform to create a seamless experience for healthcare providers and patients alike.
LTR Pharma Chairman, Lee Rodne, commented:
“This funding is a critical milestone for LTR Pharma as we advance towards commercialising SPONTAN in the US, Australia and other key markets. With our preparations for regulatory engagement underway, and with our strategic partnerships, including our co-development agreement with Aptar Pharma, we are well-positioned to bring a first-in-class, rapid-onset treatment to market.
“This marks the beginning of the next transformative chapter for LTR Pharma as we look ahead to the commercialisation of SPONTAN and pioneering innovations in nasal spray therapeutics.”